Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Medtronic Corporate Technologies and New Ventures |
---|---|
Information provided by: | Medtronic Corporate Technologies and New Ventures |
ClinicalTrials.gov Identifier: | NCT00664807 |
To generate a list of potential genetic markers that correlate with an increased risk of life-threatening arrhythmias.
To evaluate ECG-based risk markers such as heart rate variability and T-wave Alternans for their association with arrhythmic events.
Condition | Phase |
---|---|
Death, Sudden, Cardiac Ventricular Fibrillation Tachycardia Atrial Fibrillation Sick Sinus Syndrome |
Phase IV |
Study Type: | Observational |
Study Design: | Case Control, Prospective |
Official Title: | Medtronic Genetic Arrhythmia Markers for Early Detection |
Estimated Enrollment: | 1000 |
Study Start Date: | April 2008 |
Estimated Study Completion Date: | April 2009 |
Estimated Primary Completion Date: | April 2009 (Final data collection date for primary outcome measure) |
The primary objective is to establish the role of genetics in life-threatening arrhythmias leading to sudden cardiac death (SCD) and the potential utility of genetic markers in risk stratification of patients to receive an implantable cardiac defibrillator (ICD). The successful accomplishment of this goal would serve as the basis for future work on a specific diagnostic test that can be used to assess risks of threatening arrhythmias in order to quality patients for implantation of an ICD.
The secondary objectives involve more detailed analysis to search for potentially unidentified genetic markers of risk for SCD.
Ages Eligible for Study: | 40 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Primary Care Clinic, Hospitals
Inclusion Criteria:
The following criteria apply to all subjects:
Case Inclusion Criteria:
The following criteria apply to case subjects only:
Control Inclusion Criteria:
The following criteria apply to control subjects only:
Exclusion Criteria:
The following criteria apply to all subjects:
Control Exclusion Criteria:
The following criteria apply to control subjects only:
Contact: Orhan Soykan, Ph.D. | 763-505-4518 | orhan.soykan@medtronic.com |
Contact: Tara L Nahey, DVM, Ph.D. | 763-505-4599 | tara.l.nahey@medtronic.com |
United States, Arkansas | |
Arkansas Cardiology, PA | Recruiting |
Little Rock, Arkansas, United States, 72205 |
Principal Investigator: | Eric Topol, M.D. | Scripps Translational Science Institute, La Jolla, CA USA |
Principal Investigator: | Robert Kowal, M.D.,Ph.D. | HeartPlace Baylor, Dallas, TX USA |
Responsible Party: | Medtronic Corporate Technologies and New Ventures ( Tara Nahey/Senior Scientist ) |
Study ID Numbers: | MDT-CTNV-001 |
Study First Received: | April 21, 2008 |
Last Updated: | May 12, 2008 |
ClinicalTrials.gov Identifier: | NCT00664807 |
Health Authority: | United States: Food and Drug Administration |
Death Heart Diseases Tachycardia Arrhythmia, Sinus Heart Arrest Heart Block Death, Sudden |
Paroxysmal ventricular fibrillation Death, Sudden, Cardiac Atrial Fibrillation Sick Sinus Syndrome Ventricular Fibrillation Arrhythmias, Cardiac |
Disease Pathologic Processes Syndrome Cardiovascular Diseases |